viewTiziana Life Sciences PLC

Tiziana Life Sciences: HC Wainwright sees “meaningful upside” to price target if foralumab COVID-19 trial is a success

In its latest research, the US broker rates the shares a 'buy' and values them at U$11 each


A Wall Street investment bank sees “meaningful upside” to its valuation of Tiziana Life Sciences PLC (NASDAQ:TLSA; LON:TILS) if a COVID-19 trial set to get underway Brazil is a success.

Kicking off next month, the study will assess the potential of a nasal spray version of foralumab.

HC Wainwright, in research rating Tiziana shares a ‘buy’ up to US$11, said: “We note that our current valuation does not include any contribution from the use of foralumab to treat COVID-19-infected patients.

“Thus, if the Brazilian trial proves successful, this could constitute meaningful upside to our estimates.”

Foralumab, which is also advancing in two separate phase II programmes, one in Crohn's Disease and the other in progressive multiple sclerosis, is a fully human anti-CD3 monoclonal antibody.

It is being deployed to suppress an overreaction of the immune system called a cytokine storm that occurs in those worst-affected by the COVID-19 virus.

Tiziana has moved straight into human trials because it had already secured safety data for the nasal application for the drug from a phase I clinical assessment carried out a year ago.

"This is a huge milestone for the company as we have brought the time-line forward by getting it [the drug] into patients one year ahead of schedule," chairman Gabriele Cerrone said in a recent interview with Proactive's Andrew Scott.

HC Wainwright analyst Raghuram Selvaraju also used his updated research note to assess the demerger of Accustem Sciences, which was confirmed last week, and to re-affirm his US$280mln valuation of the StemPrintER diagnostic being spun off with it. 

“This would imply that the value of StemPrintER could be considered close to the entire current market cap of Tiziana, meaning that Tiziana's current pipeline of drug candidates is being assigned only nominal value,” said the analyst.

“This still provides a compelling incentive to consider an investment in Tiziana shares, in our view.”

Accustem is being floated off with the breast cancer diagnostic StemPrintER and the SPARE genomics-based personalised medicine business plus cash reserves of around £1mln.

StemPrintER is the jewel in the crown and was recently shown to outperform the best-in-class technology that was sold as part of a deal worth US$2.8bn last year, Selvaraju pointed.

The US-listed shares look set to open at around US$3.90, which means they would have 180% further to go to hit the HC Wainwright US$11 price target.

Quick facts: Tiziana Life Sciences PLC

Price: 173 GBX

Market: AIM
Market Cap: £331.19 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...


Tiziana Life Sciences: Delivery method & data 'looks promising' ahead of...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially...

on 22/9/20

2 min read